CoChat

Recruitment methods for united states Alzheimer disease prevention trials

Open access
Schneider, L.S. · 2012 · The Journal of nutrition, health and aging

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index; 2 of the 24 sources its claims cite were checked for support.

Abstract

There are no substantially effective treatments or preventatives for Alzheimer disease. The few prevention trials that were undertaken did not shown efficacy for the drugs tested; but, nevertheless, advanced prevention trials methods. We review past recruitment methods and discuss areas for improvement. Improvements in recruitment methods can enhance the likelihood for accurately demonstrating the efficacy of an effective drug. Effective therapeutics to prevent AD await discovery and proof.

Overview

CoChat Summary

TL;DR

This paper is a methods-focused review arguing that Alzheimer disease prevention trials need more proactive, registry-based recruitment, especially when trials require enriched samples or biomarker-positive participants. It concludes that large prebuilt registries and, in some settings, two-tier screening can make recruitment faster and more efficient.

Key findings

  • Recruitment time is a major driver of trial duration; in the four prevention trials discussed, recruitment ranged from 1.75 years (GEM) to 2.5 years (GuidAge), 3.7 years (ADAPT), and over 4.5 years (PREPARE), while follow-up was about 5 years in all four trials.
  • In the GEM trial using voter registration lists, 243,400 brochures were mailed, 14,603 telephone attempts were made, 12,186 (83.4%) contacts were successful, and 3,072 (25.4%) were enrolled; this was 1.3 enrolled participants per 100 brochures mailed.
  • The paper states that Medicare lists cover over 95% of residents aged typically from 62 for women and 65 for men and older in a community, making them useful for demographically representative recruitment.
  • The paper reports that recruiting by age and APOE ε4 carrier status would create a cohort with a relatively higher prevalence of positive Aβ biomarkers, about 70% using ADNI data.

Methods

  • Narrative review of recruitment methods for U.S. Alzheimer disease prevention trials, comparing direct prevention trials with add-on/nested prevention trials and drawing on examples from other prevention areas.
  • Uses published trial examples and registry-based recruitment cases, including ADAPT, GEM, GuidAge, PREPARE, WHI-MS, PREADViSE, and the use of Medicare and voter registration lists.
  • Main analysis is qualitative and methodological: it contrasts recruitment strategies, discusses assumptions behind enriched/risk-concentration sampling, and argues for registry-based and two-step biomarker screening approaches.

Limitations

  • The paper states that current prevention strategies are constrained because there are no documented, effective interventions to prevent Alzheimer disease and no such prior knowledge about whether current biomarkers must be positive for treatment response.
  • It notes that many past prevention-trial designs did not model important processes or drug-specific effects and often relied on limited control of known risk factors plus randomization for unknown biases.
  • Evident from the text: the article is a review and argument piece, not an empirical recruitment study of one trial program, so its conclusions about “what works” are based on prior trials and examples rather than new experimental comparison.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s12603-012-0011-6

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

2 Valid · 4 Not valid · 21 Not checked · 26 Own results and interpretations

18 more claims

Create a free account to see all 53 claims and to verify the 22 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 22

Metadata

Authors
Schneider, L. S.
Affiliations
University of Southern California (US)
Corresponding author
Schneider, L.S.
Venue
The Journal of nutrition, health and aging
Publisher
Elsevier BV
Published
2012-04
Volume
16
Issue
4
Pages
331-335
ISSN
1279-7707 (ISSN-L)
OpenAlex
W2041339600
Cited by
22
References
32
Citations by year
2024: 2 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2014: 2 · 2013: 1 · 2012: 1
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
Locations
  • The journal of nutrition health & aging (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Funders
Australian Government
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Keywords
Alzheimer's disease, prevention trials, trial recruitment, drug efficacy, clinical trial design
MeSH terms
Alzheimer Disease, Clinical Trials as Topic, Humans, Research Design, United States, Biomarkers, Treatment Outcome, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recruitment methods for united states Alzheimer disease prevention trials. https://app.cochat.ai/papers/10.1007/s12603-012-0011-6
The paper
Schneider, L. S. (2012). Recruitment methods for united states Alzheimer disease prevention trials. The Journal of nutrition, health and aging. https://doi.org/10.1007/s12603-012-0011-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.